{"id":447,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/de\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","title":{"rendered":"Tirzepatide Duale GIP\/GLP-1-Signalisierung: Mechanismus und Testendpunkte erkl\u00e4rt"},"content":{"rendered":"

Tirzepatide ist ein acyliertes Peptid, das entwickelt wurde, um sowohl den Glucose-abh\u00e4ngigen insulinotropen Polypeptid-Rezeptor (GIP) als auch den Glucagon-\u00e4hnlichen Peptid-1-Rezeptor (GLP-1) zu aktivieren. Um zu verstehen, dass die duale Pharmakologie die Trennung der Rezeptoraktivit\u00e4t von den in bestimmten Populationen gemessenen klinischen Ergebnissen erfordert.<\/p>

Wichtige Erkenntnisse<\/h2>
  • Tirzepatide ist ein dualer GIP\/GLP-1-Rezeptoragonist, kein \u201edreifacher Agonist\u201c.<\/li>
  • SURPASS-Studien konzentrierten sich auf die Ergebnisse von Typ-2-Diabetes; SURMOUNT-Studien konzentrierten sich auf Ergebnisse im Zusammenhang mit Fettleibigkeit.<\/li>
  • Von FDA genehmigte Daten zu Fertigarzneimitteln belegen nicht die Qualit\u00e4t, Sicherheit oder Wirksamkeit eines nicht verwandten Katalogmaterials f\u00fcr Forschungszwecke.<\/li><\/ul><\/div><\/div>
    \"Forscher
    Originale redaktionelle Illustration der Multi-Rezeptor-Peptidforschung. Es handelt sich um eine konzeptionelle Laborszene, nicht um ein Produkt- oder Behandlungsbild.<\/figcaption><\/figure>

    Was Dual-Rezeptor-Agonismus bedeutet<\/h2>

    GIP und GLP-1 sind auf N\u00e4hrstoffe reagierende Signalsysteme mit \u00fcberlappenden und unterschiedlichen Wirkungen. Tirzepatide wurde als ein Molek\u00fcl entwickelt, das beide Rezeptoren aktivieren kann. Die klinische Wirkung ist das Ergebnis der Pharmakologie, Exposition und Formulierung des gesamten Molek\u00fcls; es kann nicht durch einfaches Zusammenf\u00fcgen zweier separater Pfadbeschreibungen abgeleitet werden.<\/p>

    Das FDA-Label identifiziert Tirzepatid als Wirkstoff zugelassener verschreibungspflichtiger Produkte und beschreibt produktspezifische Indikationen, Warnhinweise und Formulierungsdetails. Diese Angaben beziehen sich auf das auf dem Etikett genannte zugelassene Fertigarzneimittel.<\/p>

    So lesen Sie die Testprogramme<\/h2>

    SURPASS-1 war eine randomisierte Phase-3-Studie bei Erwachsenen mit Diabetes vom Typ 2, der durch Ern\u00e4hrung und Bewegung nur unzureichend kontrolliert werden konnte. Der prim\u00e4re Endpunkt war die Ver\u00e4nderung des glykierten H\u00e4moglobins, wobei K\u00f6rpergewicht und Sicherheit zu den weiteren Endpunkten z\u00e4hlten. SURMOUNT-1 nahm Erwachsene mit Fettleibigkeit oder \u00dcbergewicht sowie einer gewichtsbedingten Erkrankung auf und verwendete die prozentuale Ver\u00e4nderung des K\u00f6rpergewichts als prim\u00e4ren Endpunkt.<\/p>

    Population, Vergleichsgruppe, Behandlungsdauer, Sch\u00e4tzung und Abbruchbehandlung beeinflussen die Interpretation. Ein \u00dcberschriftenprozentsatz sollte niemals von diesen Designelementen getrennt werden.<\/p>

    SURPASS-1<\/strong>Phase 3, Typ-2-Diabetes, prim\u00e4rer Endpunkt der Blutzuckerkontrolle<\/span><\/div>
    SURMOUNT-1<\/strong>Phase 3, Adipositas-\/\u00dcbergewichtspopulation, prim\u00e4rer Endpunkt K\u00f6rpergewicht<\/span><\/div>
    Regulatorische Aufzeichnung<\/strong>Produktspezifische FDA vorschreibende Informations- und Sicherheitssprache<\/span><\/div><\/div><\/div>

    Warum materielle \u00c4quivalenz wichtig ist<\/h2>

    Die Ergebnisse klinischer Studien gelten f\u00fcr die untersuchte Intervention, die unter den Bedingungen dieser Studie hergestellt und kontrolliert wird. Die Sequenzidentit\u00e4t allein zeigt keine Gleichwertigkeit hinsichtlich Reinheit, Aggregation, Gegenion, Sterilit\u00e4t, Partikelbelastung, Formulierung oder Stabilit\u00e4t.<\/p>

    F\u00fcr Katalogrecherchematerial sollten sich Forscher auf die produktspezifische Spezifikation und Chargendokumentation verlassen. Klinische Angaben zu einem zugelassenen Arzneimittel sollten nicht auf eine Produktseite f\u00fcr Forschungszwecke \u00fcbertragen werden.<\/p>","protected":false},"excerpt":{"rendered":"

    Eine evidenzbasierte Erkl\u00e4rung des Tirzepatid-Dual-Rezeptor-Agonismus und der in den SURPASS- und SURMOUNT-Studien gemessenen Endpunkte, mit klaren Grenzen f\u00fcr die Anwendung von Arzneimitteldaten auf Katalogmaterialien.<\/p>","protected":false},"author":1,"featured_media":617,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"370","pim_article_type":"Clinical evidence explainer","pim_evidence_level":"Randomized phase 3 trials and FDA labeling","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"SURPASS-1 randomized phase 3 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34186022\/\",\"note\":\"Primary clinical trial record; PMID 34186022.\"},{\"title\":\"SURMOUNT-1 obesity trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\",\"note\":\"Primary clinical trial record; PMID 35658024.\"},{\"title\":\"FDA prescribing information for Mounjaro (tirzepatide)\",\"url\":\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215866s039lbl.pdf\",\"note\":\"Approved-finished-product regulatory record.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-447","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\nTirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained - NHD<\/title>\n<meta name=\"description\" content=\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\" \/>\n<meta property=\"og:description\" content=\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\",\"name\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/de\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tirzepatide Duale GIP\/GLP-1-Signalisierung: Mechanismus und Testendpunkte erkl\u00e4rt \u2013 NHD","description":"Eine evidenzbasierte Erkl\u00e4rung des Tirzepatid-Dual-Rezeptor-Agonismus und der in den SURPASS- und SURMOUNT-Studien gemessenen Endpunkte, mit klaren Grenzen f\u00fcr die Anwendung von Arzneimitteldaten auf Katalogmaterialien.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","og_locale":"de_DE","og_type":"article","og_title":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained","og_description":"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.","og_url":"https:\/\/nhdbio.com\/de\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Verfasst von":"NHD Technical Team","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","url":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","name":"Tirzepatide Duale GIP\/GLP-1-Signalisierung: Mechanismus und Testendpunkte erkl\u00e4rt \u2013 NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Eine evidenzbasierte Erkl\u00e4rung des Tirzepatid-Dual-Rezeptor-Agonismus und der in den SURPASS- und SURMOUNT-Studien gemessenen Endpunkte, mit klaren Grenzen f\u00fcr die Anwendung von Arzneimitteldaten auf Katalogmaterialien.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD Technisches Team","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"Das technische Team von NHD verwaltet Katalogdokumentationen und Beweiszusammenfassungen f\u00fcr Forschungszwecke. Rezensierte Artikel verweisen auf von Experten begutachtete Artikel, Studienregister und beh\u00f6rdliche Aufzeichnungen, behalten Nullergebnisse und Studieneinschr\u00e4nkungen bei und unterscheiden ver\u00f6ffentlichte Interventionen von Katalogmaterialien. F\u00fcr die Strukturierung kann AI-unterst\u00fctztes Zeichnen verwendet werden; Quellenverkn\u00fcpfungen und Beweisgrenzen bleiben sichtbar. Bei dieser Arbeit handelt es sich nicht um eine unabh\u00e4ngige Begutachtung oder medizinische Beratung.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/de\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/comments?post=447"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/447\/revisions"}],"predecessor-version":[{"id":524,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/447\/revisions\/524"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/617"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/categories?post=447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/tags?post=447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}